News All of Ferrer’s information, just a click away Home News normal Apply Ferrer joins forces with leading companies to help tackle Barcelona’s challenges . Tue, 07/07/2026 - 14:47 Ferrer and Prilenia Announce Initiation of the Confirmatory PRECISE-HD Study of Pridopidine in Huntington’s Disease . Tue, 07/07/2026 - 13:58 First participant in Europe enrolled in PREVAiLS Phase 3 study of pridopidine in ALS . Tue, 06/16/2026 - 11:12 IMPAHCT marks its eighth edition, strengthening a comprehensive approach to rare lung diseases . Thu, 04/30/2026 - 10:43 Ferrer and Prilenia Announce First Participant Enrolled in the “PREVAiLS” Phase 3 Study of Pridopidine in ALS . Mon, 03/30/2026 - 07:26 Ferrer included in the ranking of the World’s Most Ethical Companies® in 2026 . Wed, 03/18/2026 - 12:05 We complete recruitment of 220 patients for the PROSPER study, a Phase II clinical trial in progressive supranuclear palsy (PSP), two months ahead of schedule . Tue, 10/21/2025 - 08:32 Nature Medicine Publishes Phase 3 Data on Pridopidine in Early-Stage Huntington’s Disease, Highlighting Impact on Clinical Progression . Fri, 09/05/2025 - 08:15 Prilenia and Ferrer Provide Update on European Regulatory Process for Pridopidine in Huntington’s Disease . Fri, 07/25/2025 - 09:55 Ferrer strengthens its impact in 2024 with increased social and environmental investment, B Corp leadership and sustainability progress . Mon, 07/21/2025 - 17:01 Cargar más For requests for interviews or information, please contact the Communications Department CONTACT US alternatively, please dial +34 936 003 779 See more R&D Strategy Business Development
Ferrer joins forces with leading companies to help tackle Barcelona’s challenges . Tue, 07/07/2026 - 14:47
Ferrer and Prilenia Announce Initiation of the Confirmatory PRECISE-HD Study of Pridopidine in Huntington’s Disease . Tue, 07/07/2026 - 13:58
First participant in Europe enrolled in PREVAiLS Phase 3 study of pridopidine in ALS . Tue, 06/16/2026 - 11:12
IMPAHCT marks its eighth edition, strengthening a comprehensive approach to rare lung diseases . Thu, 04/30/2026 - 10:43
Ferrer and Prilenia Announce First Participant Enrolled in the “PREVAiLS” Phase 3 Study of Pridopidine in ALS . Mon, 03/30/2026 - 07:26
Ferrer included in the ranking of the World’s Most Ethical Companies® in 2026 . Wed, 03/18/2026 - 12:05
We complete recruitment of 220 patients for the PROSPER study, a Phase II clinical trial in progressive supranuclear palsy (PSP), two months ahead of schedule . Tue, 10/21/2025 - 08:32
Nature Medicine Publishes Phase 3 Data on Pridopidine in Early-Stage Huntington’s Disease, Highlighting Impact on Clinical Progression . Fri, 09/05/2025 - 08:15
Prilenia and Ferrer Provide Update on European Regulatory Process for Pridopidine in Huntington’s Disease . Fri, 07/25/2025 - 09:55
Ferrer strengthens its impact in 2024 with increased social and environmental investment, B Corp leadership and sustainability progress . Mon, 07/21/2025 - 17:01